Zydus Cadila has received final approval from the US health regulator to market Azithromycin for Oral Suspension USP, used to treat bacterial infections, in the American market.
According to a company statement, the medication is used to treat respiratory infections, skin infections, ear infections and sexually transmitted diseases. The drug will be manufactured at the group’s formulations manufacturing facility at Baddi.
The Ahmedabad-based group now has 213 approvals from USFDA. Shares of Cadila Healthcare, the flagship of the Zydus Cadila Group, were trading down 1.59 per cent at Rs 375.30 on the BSE.